Bilici A, Karadag B, Doventas A, Erdincler D Suna, Cetinkaya S, Ogut G, Tezcan V, Beger T
Department of Internal Medicine, Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkey.
Neth J Med. 2004 Nov;62(10):389-92.
Retroperitoneal fibrosis (RPF) is an uncommon disorder that may cause ureteric obstruction with renal damage. Pergolide, a dopaminergic agonist used in the treatment of Parkinson's disease, has rarely been related to the development of RPF. We report on a 78-year-old woman with Parkinson's disease who presented with hydroureteronephrosis and developed RPF and serosal fibrosis during treatment with pergolide. Following discontinuation of pergolide therapy and placement of a double-J stent, her renal function improved. Inflammatory markers returned to normal limits within two months and the retroperitoneal fibrotic mass became smaller.
